- |||||||||| Review, Journal: Drugs for hypertension. (Pubmed Central) - May 21, 2024
The applicability of our method was demonstrated by the analysis of two authentic human autopsy blood samples. No abstract available
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Evaluation of multitarget drugs on the expression of cocaine-induced locomotor sensitization in male rats: A comparative study. (Pubmed Central) - May 10, 2024
No abstract available Here we compare the efficacy of mirtazapine (MIR), pindolol (PIN), fluoxetine (FLX), risperidone (RIS), trazodone (TRZ), ziprasidone (ZPR), ondansetron (OND), yohimbine (YOH), or prazosin (PRZ), to reduce long-term cocaine-induced locomotor activity and the expression of cocaine-induced locomotor sensitization in rats...After each administration, locomotor activity for each animal was recorded for 30
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Journal: Electrochemical screening of selected ?-blockers at a polarized liquid-liquid interface. (Pubmed Central) - Mar 8, 2024
The latter were compared and correlated with the available literature values of log?Poctanol. Finally, a standard addition method was used to determine the concentration of nebivolol in pharmaceutical preparations using a platform based on the electrified liquid-liquid interface.
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Feb 19, 2024
P2, N=134, Recruiting,
Finally, a standard addition method was used to determine the concentration of nebivolol in pharmaceutical preparations using a platform based on the electrified liquid-liquid interface. Trial primary completion date: Feb 2024 --> Feb 2025
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial completion, Enrollment change, Trial completion date: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Jul 3, 2023
P4, N=9, Completed,
This is the basis for the pharmacological concept of "functional affinity". Recruiting --> Completed | N=16 --> 9 | Trial completion date: Sep 2023 --> Apr 2023
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models. (Pubmed Central) - Jun 5, 2023
S-pindolol is an important candidate for clinical development in the treatment of cancer cachexia that strongly attenuates loss of body weight and lean body mass. This was also seen in the weight of individual muscles and resulted in higher grip strength.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Mar 1, 2023
P4, N=9, Active, not recruiting,
This was also seen in the weight of individual muscles and resulted in higher grip strength. Recruiting --> Active, not recruiting | N=16 --> 9 | Trial primary completion date: Dec 2022 --> Oct 2023
- |||||||||| Visken (pindolol) / Novartis
Potential of Arachis hypogaea testa as a functional food ingredient for the treatment of depression (Pennsylvania Station B/C (Crown Plaza Indianapolis Downtown Union Square)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_3544;
Pindolol (10 mg/kg), a 5HT1A receptor antagonist, reversed the antidepressant effects of C9-C3, an efficacious medium polarity fraction (p < 0.001)...Lead was detected in the testa at 4.88 ppm and a qualitative pesticide screening detected the presence of chlorflurenol and o-hydroxybiphenyl. This study confirms that Arachis hypogaea testa has the potential for commercial value as a functional food ingredient for the treatment of depression; however, heavy metals, biocides and pesticides are a food safety concern.
- |||||||||| Edsivo (celiprolol) / Acer Therap, Visken (pindolol) / Novartis, bevantolol (SOM3355) / SOM Biotech
Journal: β-arrestin2 recruitment by β-adrenergic receptor agonists and antagonists (Pubmed Central) - Jan 4, 2023
β2-AR selective antagonists butoxamine showed β-arrestin2 recruitment at β1-AR. These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands.
- |||||||||| S-oxprenolol (ACM-002) / Actimed Therap
Preclinical, Journal: The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. (Pubmed Central) - Nov 9, 2022
The performance of the adsorbent was further evaluated using environmental waters and the adsorbent demonstrated good potential for simultaneous adsorption of multicomponent pharmaceuticals. S-oxprenolol is superior to R-oxprenolol in cancer cachexia animal models and shows promise for a human application in cancer cachexia.
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date, Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Aug 22, 2022
P2, N=134, Recruiting,
The synthetic method can serve for the preparation of a broad scope of enantiomerically enriched β-blockers, the chemical structures of which rely on the common α-hydroxy-N-isopropylamine moiety, and in this sense, might be industrially attractive. Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| Visken (pindolol) / Novartis, dizocilpine (MK801) / Merck (MSD)
Preclinical, Journal: Mechanistic pathways of fibromyalgia induced by intermittent cold stress in mice is sex-dependently. (Pubmed Central) - Aug 11, 2022
Except L-arginine, MK-801 and methylene blue also attenuated this nociceptive signal in male mice, after ICS exposure. In conclusion, the modulation of serotonergic receptors, the NMDA/NO/cGMP pathway, and the oxidative stress seems contribute to nociceptive behaviors induced by ICS exposure sex-dependent.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial primary completion date: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Jun 28, 2022
P4, N=16, Recruiting,
The results demonstrate that β- and β-/β-adrenoceptor receptor antagonists act as 6-ND receptor antagonists in RIEVD, further confirming the main role of 6-ND in the RIEVD contractility. Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial primary completion date: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Jun 28, 2022
P4, N=16, Recruiting,
Trial primary completion date: Sep 2022 --> Dec 2022 Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| Visken (pindolol) / Novartis, Mikelan (carteolol) / Senju
Journal: Preparation and Evaluation of an Azobenzenediamide Bridged bis(β-Cyclodextrin)-Bonded Chiral Stationary Phase for HPLC. (Pubmed Central) - Jun 22, 2022
For example, it could resolve myclobutanil, pindolol, carteolol, betaxolol, bevanolol and bitertanol, which could not be resolved before, and should be related to the fact that the flexible N=N was more compatible with the synergistic inclusion between cavities than the rigid C=C bridge group. The azobenzenediamide bridging group could also provide hydrogen bond, π-π and other sites, which was conducive to chiral separations.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment status: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Apr 28, 2022
P4, N=16, Recruiting,
These anxiolytic-like effects seem to involve the HPA axis and 5-HT systems. Enrolling by invitation --> Recruiting
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment status: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Apr 28, 2022
P4, N=16, Recruiting,
Enrolling by invitation --> Recruiting Enrolling by invitation --> Recruiting
- |||||||||| Visken (pindolol) / Novartis
Journal: Molecular Imprinting Using a Functional Chain Transfer Agent. (Pubmed Central) - Feb 26, 2022
Selectivity studies, cross-reactivity as well as binary competitive and displacement assays showed the TGA-based MIPs to be highly selective towards PNL against pindolol and slightly competitive against atenolol. The morphologies of the polymers were shown to be affected by the concentration of the TGA, transforming into discrete macrospheres (from small aggregates) at a higher TGA concentration.
- |||||||||| Visken (pindolol) / Novartis
Clinical, PK/PD data, Journal: β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological-pharmacodynamic study. (Pubmed Central) - Feb 22, 2022
Use of moderate or high 5-HT affinity of β-adrenoceptor antagonists was associated with an increased ROR of nightmares compared with low 5-HT affinity of β-adrenoceptor antagonists (aROR moderate vs. low 1.22, 95%CI 1.04-1.43 and aROR high vs. low 2.46, 95%CI 1.93-3.13). In our large pharmacovigilance study, nightmares are more frequently reported for pindolol and metoprolol, and among β-adrenoceptor antagonists with high lipid solubility and high 5-HT receptor affinity.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma, Visken (pindolol) / Novartis
Biomarker, Journal: Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. (Pubmed Central) - Jan 27, 2022
Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka, Metopirone (metyrapone) / HRA Pharma
Review, Journal: Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. (Pubmed Central) - Jan 7, 2022
Studies on lamotrigine and pindolol reported negative results...Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.
- |||||||||| methylphenidate tablet / Generic mfg., sertraline / Generic mfg., amantadine / Generic mfg.
Clinical, Review, Journal: Pharmacological Treatment of Agitation and/or Aggression in Patients With Traumatic Brain Injury: A Systematic Review of Reviews. (Pubmed Central) - Oct 20, 2021
Atypical antipsychotics (olanzapine in particular) can be considered as practical alternatives for the as-needed management of agitation and/or aggression in lieu of benzodiazepines and haloperidol. Amantadine, β-blockers (propranolol and pindolol), antiepileptics, and methylphenidate can be considered for scheduled treatment of agitation and/or aggression in patients with TBI.
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Phase classification: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Oct 8, 2021
P2, N=134, Recruiting,
The method was successfully applied to the analysis of tap water and natural water samples, spiked with pindolol. Phase classification: P4 --> P2
- |||||||||| Myrbetriq (mirabegron) / Astellas, Visken (pindolol) / Novartis, Qsymia (topiramate/phentermine) / IEH Biopharma, Alvogen
Trial completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Oct 6, 2021
P4, N=134, Recruiting,
Phase classification: P4 --> P2 Trial completion date: Oct 2029 --> Feb 2023
- |||||||||| Visken (pindolol) / Novartis
Journal: GPCR Activation States Induced by Nanobodies and Mini-G Proteins Compared by NMR Spectroscopy. (Pubmed Central) - Sep 9, 2021
Complexes with pindolol and Nb60 induce highly similar inactive states of the receptor, closely resembling the resting state conformational ensemble...Finally, we reproduce a pharmaceutically relevant situation, where an antagonist abolishes the interaction of the receptor with the mini-G protein in a competitive manner, validating the functional integrity of our preparation. The presented system is therefore well suited for reproducing the individual steps of the activation cycle of a G protein-coupled receptor (GPCR) in vitro and serves as a basis for functional and pharmacological characterizations of more native-like systems in the future.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment status: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Jun 25, 2021
P4, N=16, Enrolling by invitation,
From a clinical point of view, these results suggest that substrates of uridine diphosphate-glucuronosyltransferase isoenzymes such as furosemide may have increased clearance during pregnancy and could require dose adjustment in this population. Recruiting --> Enrolling by invitation
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment status: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Jun 24, 2021
P4, N=16, Enrolling by invitation,
Recruiting --> Enrolling by invitation Recruiting --> Enrolling by invitation
|
